🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
The Pill That Promised a Revolution: Why Eli Lilly's Foundayo Is Launching Slower Than Wall Street Expected ◆ Speed Over Scrutiny? The High-Stakes Gamble Behind the NHS's New Fast-Track Drug Pilots ◆ A Global Milestone for Wellness: Chanelle McCoy Health Secures Historic Dual SFDA and European Novel Food Regulatory Approvals ◆ The Digital and Regulatory Frontier: Top 10 Technical and GMP Trends Shaping Pharma in 2026 ◆ Funding the Future: Inside the €75k Women TechEU and £10M Createch Grants for Startups and SMEs ◆ FDA Fires Warning Shot at Sanofi's Irish Plant Over Data Cover-Up and Altuviiio Quality Failings ◆ Top Universities in Ireland: Discover the Country's Leading Higher Education Institutions ◆ The Irish Startup Ecosystem: A Comprehensive Funding and Development Guide for Entrepreneurs ◆ The Pill That Promised a Revolution: Why Eli Lilly's Foundayo Is Launching Slower Than Wall Street Expected ◆ Speed Over Scrutiny? The High-Stakes Gamble Behind the NHS's New Fast-Track Drug Pilots ◆ A Global Milestone for Wellness: Chanelle McCoy Health Secures Historic Dual SFDA and European Novel Food Regulatory Approvals ◆ The Digital and Regulatory Frontier: Top 10 Technical and GMP Trends Shaping Pharma in 2026 ◆ Funding the Future: Inside the €75k Women TechEU and £10M Createch Grants for Startups and SMEs ◆ FDA Fires Warning Shot at Sanofi's Irish Plant Over Data Cover-Up and Altuviiio Quality Failings ◆ Top Universities in Ireland: Discover the Country's Leading Higher Education Institutions ◆ The Irish Startup Ecosystem: A Comprehensive Funding and Development Guide for Entrepreneurs ◆
Markets · 15 min delay
NBI4,187.6▲ +1.14%
PFE28.42▼ -0.38%
AZN74.18▲ +0.81%
NVO103.55▲ +2.07%
ROG261.40▼ -0.55%
ABBV174.92▲ +0.29%
EUR/USD1.0842▼ -0.12%
ISEQ9,241.3▲ +0.62%
NBI4,187.6▲ +1.14%
PFE28.42▼ -0.38%
AZN74.18▲ +0.81%
NVO103.55▲ +2.07%
ROG261.40▼ -0.55%
ABBV174.92▲ +0.29%
EUR/USD1.0842▼ -0.12%
Updated 06 Jul 2026 · EMA CTIS official data

Clinical Trials in Lithuania

← All EU trials

The most recently authorised clinical trials across the European Union - drawn live from the European Medicines Agency's Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation. Searchable by country, phase, sponsor and condition.

6
Recent authorisations
4
Phase III trials
Lithuania
Selected country
Phase III Nervous System Diseases Authorised 22/06/2026
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Non-Active Secondary Progressive Multiple Sclerosis
Non-active Secondary Progressive Multiple Sclerosis (SPMS)
Zenas Biopharma (USA) LLC · 467 participants
📍 Germany · Bulgaria · Netherlands · Sweden · Portugal · Croatia · Italy · Austria · Spain · Poland · France · Denmark · Hungary · Romania · Estonia · Slovakia · Belgium · Czechia · Norway · Lithuania · Greece
2025-524322-18-00 on CTIS ↗
Phase II Digestive System Diseases Authorised 16/06/2026
A Study to Evaluate the Long-term Safety and Efficacy of Long-acting Antibodies as Single Agents and in Combinations in Participants with Inflammatory Bowel Disease
Ulcerative colitis (Inflammatory Bowel Disease)
Spyre Therapeutics Inc. · 228 participants
📍 Croatia · Poland · Austria · Czechia · Italy · Slovakia · Bulgaria · Greece · Belgium · Spain · Hungary · Germany · Lithuania · France · Romania
2025-524640-35-00 on CTIS ↗
Phase II Digestive System Diseases Authorised 10/06/2026
J6E-MC-KWAM: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Development Program to Evaluate the Efficacy and Safety of LY4268989 (MORF-057) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis (EMERALD-3)
Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe, Ulcerative Colitis (UC)
Eli Lilly & Co. · 104 participants
📍 Latvia · Portugal · Greece · France · Czechia · Italy · Poland · Slovakia · Hungary · Croatia · Lithuania
2025-524404-29-00 on CTIS ↗
Phase III Hemic and Lymphatic Diseases Authorised 19/05/2026
A Phase 3 prospective randomised clinical trial of VMX-C001 vs usual pharmacological care in patients receiving a FXa direct oral anticoagulant (FXa DOAC) who require urgent surgery or other invasive procedure that is associated with a high risk of bleeding, with or without planned administration of heparin (EQUILIBRIX-S)
Patients on Factor Xa inhibitor treatment needing an urgent intervention associated with a high risk of bleeding
VarmX B.V. · 443 participants
📍 Belgium · Germany · Italy · France · Czechia · Bulgaria · Hungary · Spain · Netherlands · Poland · Austria · Estonia · Romania · Portugal · Lithuania
2025-521632-12-00 on CTIS ↗
Phase III Immune System Diseases Authorised 11/05/2026
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Panzyga for Prevention of Major Infections in Patients with Hypogammaglobulinemia and Autoimmune or Rheumatic Conditions Receiving Treatment with B-cell Depletion Therapy ("PROTECT")
Prevention of a Major infection in patients with Hypogammaglobulinemia and Autoimmune or Rheumatic Conditions receiving treatment with B-cell depletion therapy.
Octapharma Pharmazeutika Produktionsgesellschaft mbH · 215 participants
📍 Czechia · Lithuania · Greece · Poland · Germany · Latvia · Bulgaria · Italy
2025-522854-37-00 on CTIS ↗
Phase III Hemic and Lymphatic Diseases Authorised 17/04/2026
A Phase 3, Multicenter, Open-Label, Randomized Trial to Compare the Efficacy and Safety of Elritercept versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in ESA-naïve Adult Participants Who Require Red Blood Cell Transfusions
Myelodysplastic neoplasms/syndromes (MDS)
Takeda Development Center Americas Inc. · 114 participants
📍 France · Belgium · Germany · Italy · Bulgaria · Ireland · Lithuania · Norway · Romania · Hungary · Spain · Greece · Poland · Netherlands
2025-523544-12-00 on CTIS ↗
No trials match your search.
Cite this page

Priya Life Science (2026). EU Clinical Trials Tracker. Available at: https://priyalifescience.com/clinical-trials-europe/country/lithuania (Accessed: 6 July 2026).

Source: Clinical Trials Information System (CTIS), European Medicines Agency - trials authorised under the EU Clinical Trials Regulation (Regulation 536/2014), showing the most recent EU authorisation decisions, refreshed daily. Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See our Ireland Clinical Trials Tracker. For approved medicines, see the EMA Approvals Tracker.